5.20

0.38% -0.02

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is currently priced at $5.20, with a 24-hour trading volume of 152.10K. It has seen a -0.38% decreased in the last 24 hours and a -10.34% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $5.24 pivot point. If it approaches the $4.78 support level, significant changes may occur.

Previous Close:

$5.22

Open:

$5.3

24h Volume:

152.10K

Market Cap:

$262.66M

Revenue:

Net Income/Loss:

$-135.35M

P/E Ratio:

-2.0233

EPS:

-2.57

Net Cash Flow:

$-62.84M

1W Performance:

+7.22%

1M Performance:

-10.34%

6M Performance:

+55.22%

1Y Performance:

-7.96%

1D Range:

$5.15

$5.47

52W Range:

$2.44

$8.84

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

617-949-2643

Address

645 Summer Street, Suite 102, Boston

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GLUE's Discussions on Twitter

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

Monte Rosa Therapeutics sets public offering at $4.70 per share - Investing.com

Investing.com

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering - GlobeNewswire

GlobeNewswire

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering - Yahoo Finance

Yahoo Finance

Monte Rosa Therapeutics Shares Fall After Public Offering News - MarketWatch

MarketWatch

Monte Rosa Therapeutics launches common stock offering By Investing.com - Investing.com

Investing.com

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

GlobeNewswire

Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data

Monte Rosa Therapeutics Inc (GLUE) Net Income 2024

GLUE net income (TTM) was -$135.35 million for the quarter ending December 31, 2023, a -24.75% decrease year-over-year.

Monte Rosa Therapeutics Inc (GLUE) Cash Flow 2024

GLUE recorded a free cash flow (TTM) of -$62.84 million for the quarter ending December 31, 2023, a +40.36% increase year-over-year.

Monte Rosa Therapeutics Inc (GLUE) Earnings per Share 2024

GLUE earnings per share (TTM) was -$2.63 for the quarter ending December 31, 2023, a -14.85% decline year-over-year.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.